OppenheimerFunds Inc. grew its holdings in shares of Catalent (NYSE:CTLT) by 9.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 355,318 shares of the company’s stock after purchasing an additional 31,256 shares during the period. OppenheimerFunds Inc. owned about 0.27% of Catalent worth $14,590,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Quantbot Technologies LP purchased a new stake in Catalent during the first quarter worth about $229,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new stake in Catalent during the fourth quarter worth about $242,000. Zeke Capital Advisors LLC purchased a new stake in Catalent during the first quarter worth about $289,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Catalent by 45.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,325 shares of the company’s stock worth $301,000 after purchasing an additional 2,282 shares during the period. Finally, Eagle Boston Investment Management Inc. increased its stake in Catalent by 40.0% during the fourth quarter. Eagle Boston Investment Management Inc. now owns 7,349 shares of the company’s stock worth $306,000 after purchasing an additional 2,101 shares during the period. Institutional investors own 99.52% of the company’s stock.

CTLT stock opened at $40.21 on Wednesday. The company has a debt-to-equity ratio of 2.53, a quick ratio of 1.78 and a current ratio of 2.18. The company has a market cap of $5.29 billion, a P/E ratio of 29.79, a PEG ratio of 2.11 and a beta of 1.50. Catalent has a fifty-two week low of $33.42 and a fifty-two week high of $47.87.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, May 1st. The company reported $0.41 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.06. The firm had revenue of $627.90 million during the quarter, compared to the consensus estimate of $610.47 million. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The firm’s quarterly revenue was up 17.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.38 earnings per share. analysts anticipate that Catalent will post 1.55 EPS for the current year.

A number of analysts have issued reports on the stock. Raymond James upgraded shares of Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a research note on Wednesday, March 21st. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Thursday, March 8th. UBS Group upgraded shares of Catalent from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 21st. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, June 5th. Finally, KeyCorp upgraded shares of Catalent from a “sector weight” rating to an “overweight” rating and set a $48.00 target price on the stock in a research note on Wednesday, March 28th. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $45.67.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent (NYSE:CTLT).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.